No Data
Hong Kong Stock Market Midday Review | The Hang Seng Index fell by 0.89% in the morning session, while the Biomedical sector strengthened against the trend.
Lepu Biopharma-B (02157) rose over 18%, with significant growth in sales of Putili monoclonal antibody injection, and annual revenue increased by more than 63% year-on-year.
Hong Kong stocks movement | Lepu Biopharma-B (02157) is currently up over 24%. The sales revenue of Pudilitinib injection has significantly increased, with annual revenue rising over 63% year-on-year.
Lepu Biotech-B (02157) is currently up over 24%, as of the time of publication, it has risen 22.7%, trading at 4 Hong Kong dollars, with a turnover of 0.12 billion Hong Kong dollars.
Lepu Biotech-B (02157.HK): MRG003 clinical trial data selected for oral presentation at the 2025 ASCO Annual Meeting.
On March 27, Gelonghui reported that Lepu Biopharma-B (02157.HK) announced the results of its key pivotal Phase IIb study for its self-developed candidate drug MRG003 (an epidermal growth factor receptor ("EGFR") targeted antibody-drug conjugate ("ADC") candidate for the treatment of recurrent or metastatic nasopharyngeal carcinoma ("R/M NPC")), which has been selected for the "Major Research Abstract (LBA)" at the 2025 American Society of Clinical Oncology ("ASCO") Annual Meeting, where a verbal report will be presented. According to the disclosure, MRG003 is an EGFR-targeted monoclonal...
Lepu Biotech-B (02157) released its annual performance report with a Shareholder attributable loss of 0.411 billion yuan, an increase of 1761.77% year-on-year.
Lepu Biotech-B (02157) announced its annual performance for the year ending December 31, 2024, during which the group achieved...
Express News | Lepu Biopharma FY Adjusted Net Income RMB -429.3 Million
Express News | Lepu Biopharma FY Revenue RMB 300.3 Million
